How to Decode CIRS HLA Labs

For many people with chronic, unexplained symptoms, the road to a Chronic Inflammatory Response Syndrome (CIRS) diagnosis is anything but straightforward. Symptoms can be wide-ranging, patterns can feel inconsistent, and standard lab work fails to capture the full picture. This is part of what makes CIRS so challenging to recognize. It is a complex, multi-system condition associated with biotoxin exposure in susceptible individuals, and proper evaluation requires looking beyond a single symptom, trigger, or test result.

 

One piece of the diagnostic puzzle, according to the criteria developed by Dr. Ritchie Shoemaker, is HLA gene testing. This lab is designed to assess whether someone may carry genetic patterns associated with increased susceptibility to developing CIRS. For patients reviewing their results, however, the numbers and haplotypes can quickly become confusing. What do these HLA types actually mean? How much weight should they carry? And how useful are they in the bigger picture of diagnosis and treatment?

 

Let’s break it all down. We’ll review the broader CIRS diagnostic criteria, explain the role of HLA gene testing, and show you how to decode your lab work. We’ll also discuss what these HLA types may suggest, how this information can be used clinically, and where the limitations matter so you can interpret your results with more clarity, nuance, and confidence.

 

Key Takeaways

• CIRS is a complex, multi-system illness, which is why diagnosis requires multiple criteria.
• HLA-DR/DQ testing helps assess genetic susceptibility to biotoxin illness, but it doesn’t diagnose CIRS on its own.
• The Shoemaker framework uses five criteria to evaluate CIRS, including exposure history, symptom clusters, VCS testing, blood markers, and treatment response.
• Decoding HLA labs involves translating your alleles, forming haplotypes, and comparing them to known susceptibility patterns.
• A susceptible haplotype can provide helpful context for treatment and prevention, but it doesn’t determine how severe your case will be or how your healing will unfold.
• Some people without classic HLA susceptibility can still develop CIRS, which is why genetics must always be interpreted within the full clinical picture.
• Understanding your haplotype can be empowering when it is used to guide more personalized, informed decisions about long-term care.

 

 

What Is CIRS?

 

 

Chronic Inflammatory Response Syndrome (CIRS) is a chronic, biotoxin-triggered illness that can disrupt multiple body systems at once, which is why it often presents with a broad and confusing symptom picture. Rather than following a neat or predictable pattern, CIRS can affect cognition, energy, sleep, mood, digestion, hormones, and pain signaling in ways that may seem disconnected on the surface. What ties these symptoms together is an ongoing inflammatory response that the body struggles to shut down appropriately.

 

This is also why CIRS can be so difficult to identify through conventional care alone. Many patients don’t show obvious abnormalities on standard testing, even while their day-to-day functioning continues to decline. Recognizing CIRS usually requires stepping back to look at the full context, including symptom patterns, exposure history, and targeted markers that help reveal whether a biotoxin-driven inflammatory process may be at play.

 

Because the presentation is so wide-ranging, CIRS is commonly overlooked, misunderstood, or mistaken for other chronic conditions. Some individuals are told their labs are normal, while others receive multiple diagnoses that still don’t fully explain the bigger picture. A more complete evaluation helps connect those dots. When the underlying inflammatory process is properly identified, treatment can become more focused, moving beyond temporary symptom management toward addressing the root drivers that are keeping the body stuck.

 

 

CIRS is usually set in motion by exposures that the immune system cannot clear or regulate well. Instead of resolving normally, the body can remain stuck in a prolonged inflammatory response. These triggers are not limited to one source and may come from environmental, infectious, or toxin-related exposures, including the following:

 

• Water-damaged buildings: One of the most common patterns seen in CIRS involves exposure to indoor spaces with current or past water damage. These environments may contain mold spores, mold fragments, bacterial byproducts, and other microbial particles that circulate in the air and continue to provoke immune reactivity. Even when mold is no longer actively growing, leftover particulate matter can still contribute to ongoing symptoms.
• Tick-borne and vector-borne illnesses: Infections linked to bites from ticks and other insects, including pathogens associated with Lyme disease and co-infections, may act as inflammatory triggers in some cases. Certain venom-related exposures have also been discussed as possible initiating events when they create a significant immune disruption.
• Biotoxins in seafood: Some reef fish can contain toxins produced by marine algae, particularly when those toxins become concentrated higher up the food chain. Because larger predatory fish accumulate more of these compounds over time, they are generally associated with greater exposure risk.
• Algal toxin exposure from water sources: Freshwater and coastal algal blooms can release compounds that affect human health through drinking contaminated water, breathing in aerosolized particles, or direct skin exposure. In susceptible individuals, these exposures may contribute to persistent inflammatory symptoms.
• Other compounding exposures: Additional burdens such as chronic infections, endotoxins, volatile organic compounds (VOCs), actinomycetes, and certain medical or environmental stressors may also play a role. In some individuals, it is not a single trigger but the cumulative effect of multiple immune stressors that helps drive the illness forward.

 

 

Biotoxins are tiny biologically active compounds that can interfere with normal immune communication and contribute to widespread symptoms. Because they are small and highly reactive, their effects are not always obvious on standard lab testing. Although exposure to contaminated indoor air from water-damaged buildings is one of the best-known sources, biotoxins may also come from food, infectious exposures, or contaminated water.

 

At the same time, exposure alone is not enough to explain why one person develops CIRS while another does not. The outcome usually depends on the interaction between genetic susceptibility and the body’s overall stress load. Immune resilience can be challenged by infections, surgery, pregnancy, chemical exposures, or prolonged psychological stress, all of which may amplify inflammatory signaling. In those with certain HLA-DR patterns, that added burden may make it harder for the body to return to immune balance after a triggering exposure.

 

Many people are exposed to biotoxins and recover without long-term consequences. But in susceptible individuals, the body may have more difficulty identifying, binding, and clearing these compounds efficiently. When that happens, inflammatory pathways can stay active far longer than they should, contributing to a chronic, multi-system illness picture. For some, this shift feels sudden and dramatic. For others, it develops more gradually over time, making the connection harder to recognize.

 

For a more detailed understanding of CIRS, click here.

 

What Is the Shoemaker Protocol?

 

 

Developed by Dr. Ritchie Shoemaker, the Shoemaker Protocol is a stepwise, research-informed framework designed to evaluate and treat Chronic Inflammatory Response Syndrome (CIRS) and related biotoxin illnesses. Its purpose is not simply to suppress symptoms, but to address the underlying inflammatory and immune dysregulation that keeps the illness going. By following a specific clinical sequence, the protocol aims to reduce biotoxin burden, calm persistent immune activation, and restore more normal physiological function over time.

 

The protocol includes a series of targeted interventions that are introduced in a deliberate order. These involve getting out of ongoing exposure as well as therapies to support toxin binding and clearance, address abnormal inflammatory markers, improve hormonal and neurological signaling, and help the body regain better immune regulation. Later-stage treatments, such as VIP therapy, are typically considered only after earlier foundational steps have been completed, and objective markers suggest that the body is ready.

 

While the treatment side of the Shoemaker Protocol is often what gets the most attention, Shoemaker also established a broader framework for identifying CIRS in the first place. That diagnostic model uses a combination of history, symptoms, clinical findings, and laboratory data to determine whether the condition is likely present. Before understanding where HLA testing fits in, it helps to first look at the Shoemaker criteria used to diagnose CIRS.

 

What Is the Diagnostic Criteria for CIRS?

 

 

Since CIRS is a complex, multi-system illness, diagnosis can’t be made based on one symptom, one exposure, or one lab result alone. Biotoxins can affect the immune, neurological, hormonal, digestive, and metabolic systems in ways that create a broad and often overlapping symptom picture, which is why a more structured diagnostic framework is needed. This complexity also helps explain why CIRS is frequently missed or misunderstood in conventional care.

 

The potential scope of this condition is significant. According to the Environmental Protection Agency, roughly 50% of homes and 85% of commercial buildings have water damage, creating widespread potential for biotoxin exposure. When this is considered alongside the estimate that about 25% of the population may carry genetic susceptibility to CIRS, it suggests that millions of Americans could be affected.

 

To bring more clarity to diagnosis, Shoemaker established five key criteria used to identify CIRS. Rather than relying on a single finding, these criteria help practitioners evaluate whether a patient’s symptom patterns, history, and objective data fit the larger picture of this condition.

 

Pro-Tip: The first three steps below can be completed on your own and are the best place to start if you’re struggling with root-cause healing or mystery symptoms. 

 

Criterion One: Exposure History

 

 

The first criterion in the Shoemaker model is a relevant exposure history. Since water-damaged buildings are believed to account for the majority of CIRS cases, this part of the evaluation usually starts by looking closely at the environments you have lived in, worked in, attended school in, or otherwise spent significant time inside.

 

Exposure isn’t always dramatic or obvious. In many cases, it involves subtler clues such as a past roof leak, plumbing issue, basement dampness, warped flooring, stained ceiling tiles, musty odors, condensation problems, or a workplace with chronic water intrusion.

 

This review matters because many individuals with CIRS don’t immediately recognize or remember their exposures, especially when brain fog and memory issues are already part of the illness picture. A building doesn’t need to be visibly covered in mold to be relevant. Even past water damage, hidden moisture behind walls, or contamination in HVAC systems can contribute to exposure. For that reason, it can be helpful to make a written timeline of the homes, apartments, offices, schools, and other indoor spaces tied to the onset or worsening of symptoms.

 

Although water-damaged environments are the most common trigger, they are not the only ones that matter. Other important exposures include tick bites and other vector-borne illnesses, recluse spider bites or certain venomous bites, sewage backups, direct contact with stagnant or algae-contaminated water, and seafood poisoning associated with biotoxin exposure. A history of traumatic brain injury (TBI) can also be clinically relevant, since brain injury can overlap with or intensify the inflammatory and neurological patterns seen in CIRS.

 

In some cases, certain viral infections can also be considered part of the broader exposure and illness history, particularly when symptoms began or significantly escalated after the infection.

 

The goal of this criterion is to identify whether there is a plausible trigger that fits the larger CIRS picture. Writing down possible exposure events, symptom onset, major health changes, and the timing of illness flares can make this pattern easier to see. 

 

Criterion Two: Symptom Clusters

 

 

After identifying relevant exposure history, the next step is reviewing symptom clusters. This matters because CIRS can affect many systems of the body at the same time, which is why symptoms can seem widespread, inconsistent, or easy to confuse with other chronic illnesses. On their own, individual symptoms like fatigue, brain fog, joint pain, headaches, sinus issues, or mood changes don’t confirm CIRS. The bigger question is whether those symptoms form a pattern that reflects the biotoxin illness pathway.

 

To help identify that pattern, Shoemaker grouped symptoms into 13 clusters based on how CIRS commonly disrupts different physiological systems. These clusters capture the multi-system nature of the illness rather than focusing on one isolated complaint. For this criterion, a cluster is considered positive if you have at least one symptom within that group. If you have symptoms in at least eight of the 13 clusters, along with a relevant exposure history, that raises suspicion and supports moving forward with the rest of the diagnostic workup.

 

This step is especially helpful because many people with CIRS have spent years chasing separate explanations for seemingly unrelated issues. They may have seen one provider for migraines, another for digestive symptoms, another for hormone changes, and another for sleep or cognitive concerns. Symptom clustering helps pull those scattered complaints into one bigger clinical picture. It also gives practitioners a more standardized way to assess whether the pattern is consistent with CIRS rather than relying only on a general impression of feeling unwell.

 

Pro-Tip: It isn’t uncommon for people actively eating a Carnivore diet to fall short of eight out of 13 symptom clusters, even when they still have CIRS. Since Carnivore is one of the most anti-inflammatory dietary approaches, it can reduce or mask many of the more obvious symptoms that would otherwise make clusters test positive. If this applies to you, it can be helpful to think back to what your symptoms looked like before starting Carnivore. And if you meet the other diagnostic criteria, this may help explain why you don’t show as many positive symptom clusters on paper.

 

Criterion Three: Visual Contrast Sensitivity (VCS) Test

 

 

Once you’ve identified a relevant exposure history and symptoms across at least eight of the 13 clusters, next up is the Visual Contrast Sensitivity (VCS) test. This is a non-invasive screening tool used to assess whether the visual and neurological systems may be showing patterns consistent with biotoxin illness. It gives the diagnostic process a more objective layer, rather than relying on symptoms alone.

 

The VCS test measures how well you can distinguish between shades of light and dark as contrast becomes more subtle. In other words, it looks at your ability to detect differences in low-contrast visual patterns. The test itself involves viewing a series of images or lines that gradually become harder to distinguish. Reduced performance may reflect functional changes in the visual pathways and nervous system, both of which can be affected in CIRS.

 

The inflammatory cascade can impair oxygen delivery and blood flow at the capillary level, including within the optic system. When this happens, the small vessels serving the optic nerve and related visual structures may not function optimally, which can contribute to decreased contrast sensitivity. That is why the VCS test is used as an indirect marker of the downstream effects of the biotoxin response.

 

Historically, contrast sensitivity testing was developed as an objective way to evaluate functional health and performance, and it is still used in certain settings today. In the context of CIRS, it has become one of the most recognized screening tools because it is relatively simple, accessible, and clinically useful when interpreted alongside the rest of the diagnostic picture.

 

That said, the VCS test is not meant to stand alone. A failed test doesn’t automatically prove someone has CIRS, and a normal result doesn’t completely rule it out. False passes can occur, and some people have abnormal results for other reasons, including other neurological or eye-related issues. Even so, when someone has a compatible exposure history, enough positive symptom clusters, and then fails the VCS test, it adds meaningful support to the suspicion that CIRS may be present.

 

For readers moving through this process on their own, the VCS test is usually the first objective checkpoint after symptom review. It helps determine whether it makes sense to proceed with more specialized labs and the remaining diagnostic criteria.

 

Criterion Four: CIRS Markers Blood Work

 

 

 

After exposure history, symptom clusters, and the VCS test, specialized blood work is the next criterion for CIRS diagnosis. This is where the diagnostic process becomes more objective. Since CIRS affects immune signaling, inflammation, hormones, and fluid balance, the following panel of markers looks for patterns that are commonly seen in biotoxin illness. No single lab confirms CIRS on its own, but when several abnormal markers appear together in the right clinical context, they can strongly support the diagnosis.

 

Below is an overview of the blood markers commonly used in a CIRS workup:

 

• HLA-DR/DQ haplotypes: This is a genetic test that looks at specific immune-related gene patterns associated with biotoxin susceptibility. It is used to assess whether someone may be genetically predisposed to having more difficulty recognizing and clearing biotoxins, which can increase vulnerability to developing CIRS after exposure.
• TGF-beta 1 (Transforming Growth Factor beta 1): This is an immune signaling molecule involved in inflammation, tissue remodeling, and immune regulation. It is included because it is usually elevated in CIRS and may reflect ongoing inflammatory activity, immune dysregulation, and downstream effects on multiple body systems.
• C4a: C4a is part of the complement system, which helps regulate immune responses. It is used in CIRS testing because elevated levels can indicate activation of inflammatory pathways typically associated with biotoxin exposure.
• MMP-9 (Matrix Metalloproteinase-9): MMP-9 is an inflammatory enzyme involved in breaking down the extracellular matrix and affecting tissue permeability. In CIRS, it is used as a marker of inflammatory activation that may contribute to symptoms by allowing inflammatory compounds to move more easily into tissues.
• VEGF (Vascular Endothelial Growth Factor): VEGF helps regulate blood vessel function and oxygen delivery to tissues. It is measured because low VEGF is commonly seen in CIRS and may help explain symptoms related to poor oxygenation, fatigue, exercise intolerance, and impaired capillary circulation.
• MSH (Melanocyte-Stimulating Hormone): MSH is a regulatory hormone involved in immune balance, sleep, pain perception, gut integrity, and mucosal defense. It is often low in CIRS, which is why it is included as part of the broader picture of neuroimmune and hormonal disruption.
• ADH (Antidiuretic Hormone) and osmolality: These two markers are typically interpreted together to assess fluid regulation and thirst signaling. In CIRS, abnormalities in ADH and osmolality may reflect disrupted hypothalamic regulation, which can contribute to excessive thirst, frequent urination, dehydration tendencies, or problems maintaining fluid balance.
• Leptin: Leptin is a hormone involved in appetite regulation, metabolism, and inflammatory signaling. It may be included because abnormal leptin levels can reflect metabolic dysfunction and inflammatory stress, both of which may be part of the CIRS picture in some patients.
• VIP (Vasoactive Intestinal Peptide): VIP is a neuropeptide that supports anti-inflammatory signaling, gut function, blood flow, and the regulation of several body systems. Low VIP is commonly seen in more advanced or persistent CIRS cases and can reflect broader loss of regulatory balance.
• ACTH and cortisol: These markers help evaluate the hypothalamic-pituitary-adrenal (HPA) axis and the body’s stress response. They are used because CIRS can disrupt normal neuroendocrine signaling, sometimes leading to abnormal cortisol patterns or impaired adaptation to stress.
• Antigliadin antibodies (AGA): These antibodies reflect immune reactivity to gliadin, a component of gluten. In the Shoemaker framework, they are sometimes used because biotoxin illness can increase gut permeability and immune reactivity, making antigliadin antibodies one possible marker of downstream immune disruption.

 

Pro-Tip: With the exception of HLA testing, which only needs to be done once because your genetics don’t change, these markers can be repeated throughout treatment to help track progress. Tracking them over time can provide useful insight into whether inflammation is calming, regulatory pathways are improving, and the body is moving in the right direction clinically.

 

Criterion Five: Improvement Through the Shoemaker Protocol

 

 

The final criterion in the diagnostic process is clinical improvement with treatment. This is important because CIRS is ultimately a pattern-based diagnosis. In real practice, some patients don’t fit the textbook picture. They may not show classic HLA susceptibility, may pass the VCS test, may not meet 8 out of 13 symptom clusters, or may have blood work that is suggestive but not fully classic. Even so, if the larger story fits and they improve in a meaningful way as the inflammatory pathway is addressed, that response can provide significant confirmation that CIRS was part of the underlying problem.

 

This criterion is especially valuable because it reflects how complex and variable biotoxin illness can be. CIRS doesn’t always present the same way in every patient, and the degree of abnormality on testing can be influenced by a variety of factors. A patient may look less obvious on paper but still respond clearly once the inflammatory drivers are properly addressed. In that sense, improvement through treatment helps connect the clinical dots when the rest of the picture is supportive but not straightforward.

 

While it isn’t one of the five formal diagnostic criteria, nasal testing for MARCoNS can offer another useful clue in the right patient. When MSH is low, MARCoNS are present in more than 80% of cases, and in patients with normal MSH, MARCoNS are present in less than 2% of cases. Due to that association, a positive deep nasal culture can strengthen suspicion that the biotoxin pathway is active and help explain why some patients remain stuck.

 

It is also worth noting that MARCoNS is not the only possible nasal finding. Some patients instead grow Staphylococcus aureus or other organisms on nasal culture. 

 

HLA-DR/DQ Haplotypes for CIRS

 

 

HLA-DR/DQ haplotype testing is only done once. Unlike inflammatory markers that can rise or fall over the course of treatment, HLA testing looks at inherited genetic patterns, and your genetics don’t change. Its purpose is to provide a one-time snapshot of whether you carry certain immune-related haplotypes associated with increased susceptibility to biotoxin illness and CIRS.

 

Knowing your haplotype can be helpful, but it should be viewed with the same balanced perspective as any other genetic test. On the benefit side, it can offer useful context about whether your immune system may be more vulnerable to struggling with certain biotoxin exposures. It can also help explain why one person becomes chronically ill after an exposure while another person in the same environment doesn’t.

 

However, HLA testing has clear limitations. It doesn’t diagnose CIRS by itself, it doesn’t predict exactly how sick someone will become, and it doesn’t determine what recovery will look like. Like other gene-based testing, it provides risk context and not a complete clinical answer.

 

This nuance is important because not every person with CIRS has a recognized HLA susceptibility pattern. It is estimated that around 5% of CIRS cases don’t show the classic genetic susceptibility associated with the condition. That means a non-susceptible HLA result doesn’t automatically rule CIRS out, especially if the rest of the clinical picture strongly fits. Genetics can inform the story, but they are still only one piece of a much larger diagnostic framework.

 

It is also important to remember that mold, Lyme disease, and other biotoxin exposures can affect people in many ways outside of CIRS. Some individuals may experience acute illness, transient inflammation, symptom flares, or other health effects without developing the full chronic inflammatory pattern that defines CIRS. In other words, biotoxin exposure can still be harmful even when someone doesn’t have genetic susceptibility or meet the full criteria for this diagnosis.

 

Decoding HLA-DR/DQ Labs

 

 

Before decoding your HLA results, it helps to understand what this test is actually measuring.

 

HLA-DR and HLA-DQ proteins are found on antigen-presenting cells such as macrophages, B cells, and dendritic cells. Their job is to present foreign material from outside the cell to naïve T lymphocytes so the immune system can recognize what needs to be addressed. T lymphocytes then help coordinate the elimination of the antigen and signal B lymphocytes so that future recognition and removal are more efficient. Because of this, the structure of HLA-DR molecules plays an important role in early peptide and antigen recognition.

 

In CIRS-related interpretation, the alleles most often evaluated for chronic illness susceptibility are DRB1, DQ, DRB3, DRB4, and DRB5.

 

Just as we inherit blood type traits from our parents, we also inherit HLA patterns related to white blood cell immune signaling. But unlike red blood cell typing, HLA inheritance creates far more possible combinations, resulting in more than 50 known HLA types. Some of these haplotypes are associated with greater susceptibility to certain biotoxin-related illnesses, while others are considered lower risk or to have no known susceptibility.

 

With that context in mind, decoding HLA results is usually a three-step process.

 

The first step is identifying the key two-digit values from the five main categories on the lab report: DRB1, DQ, DRB3, DRB4, and DRB5. These values are then translated according to the interpretation rules used for Shoemaker-style haplotype analysis.

 

The second step is organizing those translated values into the correct haplotype groupings and comparing them against the recognized susceptibility patterns associated with CIRS. Rather than reading each number on its own, the goal is to see how the values combine to form specific haplotypes.

 

The final step is determining whether any of those pairings match a known susceptible pattern. If at least one qualifying combination is present, the person is considered genetically susceptible based on HLA haplotype testing. 

 

Step One: How to Convert Lab Numbers

 

 

When decoding your HLA results, each section is handled a little differently:

 

DRB1
If you see 03, convert it to 17.
All other numbers stay the same.
If only one number is listed, write it twice.

 

DQ
Leave the number exactly as it appears.
If only one number is listed, write it twice.

 

DRB3
Convert 01 to 52A.
Convert 02 to 52B.
Convert 03 to 52C.
If this section is blank, leave it blank.
If only one value is listed, you may need to write it twice.

 

DRB4
If this section is present, record it as 53.
If it is blank, leave it blank.
If only one value is listed, you may need to write it twice.

 

DRB5
If this section is present, record it as 51.
If it is blank, leave it blank.
If only one value is listed, you may need to write it twice.

 

A helpful nuance to keep in mind is that DRB3, DRB4, and DRB5 need to be interpreted together. If only one allele appears across those three sections, you may need to duplicate it, but this depends on how the DRB1 and DQ values line up with the known susceptible haplotypes.

 

Step Two: How to Combine Alleles

 

 

 

Once you have translated the values, the next step is to sort them into three buckets:

 

• Bucket 1: your two DRB1 numbers
• Bucket 2: your two DQ numbers
• Bucket 3: your DRB3, DRB4, and/or DRB5 values, which may give you zero, one, or two entries

 

From there, you build possible haplotype combinations by placing each value into its correct position. DRB1 values can only go in the first position, DQ values can only go in the second position, and DRB3/DRB4/DRB5 values can only go in the third position. You cannot swap them across positions.

 

The goal is to combine the values from each bucket in valid ways and compare them to the known CIRS-associated haplotypes. As you do this, each number or number-letter combination can only be used once in a given pairing. If one or more of the combinations you create matches a recognized susceptible haplotype, that pattern may indicate genetic susceptibility.

 

Step Three: Interpret the Results

 

 

Once you decode your HLA results, the next step is comparing your haplotypes to the known patterns associated with mold illness, Lyme-related illness, multi-biotoxin susceptibility, and other clinical patterns observed in Shoemaker’s work. Some haplotypes are considered higher risk, some are linked to more specific exposures, and others are considered lower risk or to have no known susceptibility.

 

Here are the CIRS haplotypes from Shoemaker’s research: 

 

• Multiple biotoxin susceptibility: 11-3-52B, 12-3-52B, 4-3-53, 14-5-52B
• Mold susceptibility: 7-2-53, 7-3-53, 13-6-52A, 13-6-52B, 13-6-52C, 17-2-52A, 18-4-52A
• Chronic Lyme susceptibility: 15-6-51, 16-5-51
• Dinoflagellate or ciguatera-type fish toxin susceptibility: 4-7-53, 4-8-53
• MARCoNS-associated pattern: 11-7-52B
• Low MSH-associated pattern: 1-5
• Multiple sclerosis-associated pattern: 15-6-51
• Chronic fatigue-associated patterns: 4-3-53, 11-3-52B
• Chronic fatigue associated with the former Lyme vaccine Lymerix: 4-3-53
  • Most concerning DRB1 subtypes within this pattern: 0401, 0402, 0404
• Haplotype associated with Gardasil caution: 11-3-52B
• Lower mold risk: 7-9-83, 9-9-53, 12-7-52B
• Low-risk mold patterns: 7-9-53, 12-7-52B, 9-3-53, 9-9-53
• No known susceptibility: 8-3, 8-4, 8-6

 

Pro-Tip: If you think you’re suffering from CIRS and need help with HLA testing or interpreting your results, our private practice, Empower Functional Health, can help. Our CIRS Testing includes HLA interpretation and comprehensive diagnostic reports.

 

Understanding Your CIRS Haplotype

 

 

Your CIRS haplotype can offer helpful context, but it should be interpreted as a measure of susceptibility, not certainty. Roughly 24% of the US population carries HLA patterns associated with biotoxin susceptibility, and these individuals make up about 95% of diagnosed CIRS cases.

 

That means genetics isn’t the whole story. As a reminder, around 5% of people with CIRS don’t have a recognized susceptible haplotype, which is why HLA results should always be interpreted alongside symptoms, exposure history, VCS testing, blood markers, and clinical response to treatment.

 

One of the most important nuances is that a susceptible haplotype doesn’t mean you automatically have CIRS. It means your immune system may be more likely to struggle with clearing certain biotoxins after exposure, which can increase the risk of developing chronic inflammatory illness. On the other hand, a lower-risk or no-known-susceptibility pattern doesn’t fully rule CIRS out either. Some people without classic susceptibility still become ill.

 

It is also helpful to understand that not all susceptible haplotypes carry the same clinical meaning. Some are linked more strongly with mold-related illness, others with chronic Lyme patterns, and others with broader multi-biotoxin susceptibility. In practice, this can sometimes help explain why one person seems especially reactive to water-damaged buildings, while another has a more complex history involving mold, Lyme, or multiple overlapping triggers. Even so, the treatment approach usually overlaps significantly, since the broader goal is still to address the inflammatory biotoxin pathway rather than focusing only on the label attached to the haplotype.

 

Certain haplotypes also come with added clinical nuance. For example, 11-3-52B is often viewed as one of the more challenging patterns. In clinical discussion, it has been associated with people who may get sicker faster after exposure, particularly when TGF-beta 1 is very elevated. This pattern has also been linked with more complex presentations involving pain, connective tissue-related symptoms, dysautonomia, mast cell activation, and somatic dysfunction. While that doesn’t mean every person with 11-3-52B will experience those issues, it does mean this haplotype may deserve closer clinical attention.

 

Another nuance involves the 1-5 haplotype. Its significance is less straightforward than some of the more clearly defined mold or multi-susceptible patterns. In Surviving Mold, Shoemaker discussed 1-5 in connection with low MSH, and in later discussions, he also referenced related patterns such as 10-5, 103-5, 1-3, and 1-4. So while 1-5 may not be emphasized in every summary chart, it may still have clinical relevance, particularly in patients with low MSH-related patterns.

 

HLA results can also be useful when looking at Lyme-related cases. If someone with Lyme symptoms doesn’t carry a Lyme-susceptible or multi-susceptible haplotype, there may be a greater chance they respond well to antibiotics alone. But if they do carry one of those haplotypes and are not improving as expected, that can be a clue that the biotoxin pathway is still active and needs to be addressed. In those cases, prolonged antibiotics alone may not be enough because the problem is no longer just the infection itself, but the inflammatory response and impaired toxin clearance that persist afterward.

 

Ultimately, understanding your CIRS haplotype is about gaining potential context. These patterns can help explain risk, guide clinical thinking, and sometimes clarify why your illness behaves the way it does.

 

Pro-Tip: In clinical practice, HLA results don’t always predict how straightforward or difficult someone’s healing process will be. We have seen patients who were labeled as broadly biotoxin-susceptible but also carried a Lyme-associated haplotype, and we have also seen individuals with the “dreaded” multiple-susceptible patterns move through treatment with fewer roadblocks than patients without those same gene types. Genetic testing can provide a useful layer of context, but it is never definitive when it comes to forecasting treatment response. Every CIRS case is highly individualized, which is why outcomes depend on the full clinical picture and a personalized treatment approach rather than haplotype patterns alone.

 

CIRS Haplotype FAQ

Here are some of our most frequently asked questions regarding CIRS haplotypes:[/vc_column_text]

Closing Thoughts On CIRS HLA-DR/DQ Haplotypes

Learning your CIRS HLA-DR/DQ haplotype can feel overwhelming at first, especially when the terminology is unfamiliar and the implications seem significant.

 

But this information is best viewed as another meaningful piece of the puzzle and not a fixed prediction of your future health. Haplotype testing can offer helpful insight into susceptibility, guide treatment planning, and support more informed prevention decisions, but it should never be interpreted as a definitive destiny.

 

A helpful way to think about genetics is that they may load the gun, but the environment pulls the trigger. In other words, your genes may influence vulnerability, but they don’t guarantee illness, determine the severity of your case, or decide how well you can heal. Various other factors all play major roles in how CIRS develops and how recovery unfolds.

 

This is why personalized care matters so much. Working with a knowledgeable practitioner can help you understand what your haplotype actually means, how much weight to give it in the context of your full case, and how it fits into both your current treatment plan and long-term prevention strategy.

 

When interpreted thoughtfully, this information can be deeply empowering. Rather than something to fear, it can become a tool that helps you make more informed decisions, better understand your body, and move forward in care with greater clarity, confidence, and hope.

 

Work With Our Trusted CIRS Functional Medicine Practitioners

Our Empower Functional Health practice is honored to be trusted CIRS functional practitioners, supporting patients and clients from around the globe. We’re passionate about helping individuals achieve root-cause healing in order to live the life they are meant to, nearly symptom-free. We provide environmental illness thought leadership and evidence-based insights, paired with clinical pearls, to help you achieve your wellness goals. We welcome you to explore our free resources, and if you find that self-troubleshooting falls short, we’re here to guide you with personalized support and protocols. If you believe you’re suffering from CIRS, our CIRS Testing + Session is the best place to start.

 

 

DISCLAIMER: This content is for educational purposes only. While we are board-certified in holistic nutrition and are functional practitioners, we are not providing medical advice. Whenever you start a new diet or protocol, always consult with your trusted practitioner first.